Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
Digital
- Autores:
-
Gerstein, Hertzel C.
Colhoun, Helen M.
Dagenais, Gilles R.
Diaz, Rafael
Lakshmanan, Mark
Pais, Prem
Probstfield, Jeffrey
Riddle, Matthew C.
Ryden, Lars
Xavier, Denis
Atisso, Charles M.
Avezum, Alvaro
Basile, Jan
Chung, Namsik
Conget, Ignacio
Cushman, William C.
Franek, Edward
Hancu, Nicolae
Hanefeld, Markolf
Holt, Shaun
Jansky, Petr
Keltai, Matyas
Lanas, Fernando
Leiter, Lawrence A.
Lopez-Jaramillo, Patricio
Cardona-Munoz, Ernesto G.
Pirags, Valdis
Pogosova, Nana
Raubenheimer, Peter J.
Shaw, Jonathan
Sheu, Wayne H-H.
Temelkova-Kurktschiev, Theodora
The REWIND Trial Investigators
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2018
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/6095
- Palabra clave:
- Rights
- closedAccess
- License
- © The Authors, John Wiley & Sons Ltd, 2018
| id |
RUDES2_1b5a0c401444004a7310155093cff3b9 |
|---|---|
| oai_identifier_str |
oai:repositorio.udes.edu.co:001/6095 |
| network_acronym_str |
RUDES2 |
| network_name_str |
Repositorio Universidad de Santander |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide |
| title |
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide |
| spellingShingle |
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide |
| title_short |
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide |
| title_full |
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide |
| title_fullStr |
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide |
| title_full_unstemmed |
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide |
| title_sort |
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide |
| dc.creator.fl_str_mv |
Gerstein, Hertzel C. Colhoun, Helen M. Dagenais, Gilles R. Diaz, Rafael Lakshmanan, Mark Pais, Prem Probstfield, Jeffrey Riddle, Matthew C. Ryden, Lars Xavier, Denis Atisso, Charles M. Avezum, Alvaro Basile, Jan Chung, Namsik Conget, Ignacio Cushman, William C. Franek, Edward Hancu, Nicolae Hanefeld, Markolf Holt, Shaun Jansky, Petr Keltai, Matyas Lanas, Fernando Leiter, Lawrence A. Lopez-Jaramillo, Patricio Cardona-Munoz, Ernesto G. Pirags, Valdis Pogosova, Nana Raubenheimer, Peter J. Shaw, Jonathan Sheu, Wayne H-H. Temelkova-Kurktschiev, Theodora The REWIND Trial Investigators |
| dc.contributor.author.none.fl_str_mv |
Gerstein, Hertzel C. Colhoun, Helen M. Dagenais, Gilles R. Diaz, Rafael Lakshmanan, Mark Pais, Prem Probstfield, Jeffrey Riddle, Matthew C. Ryden, Lars Xavier, Denis Atisso, Charles M. Avezum, Alvaro Basile, Jan Chung, Namsik Conget, Ignacio Cushman, William C. Franek, Edward Hancu, Nicolae Hanefeld, Markolf Holt, Shaun Jansky, Petr Keltai, Matyas Lanas, Fernando Leiter, Lawrence A. Lopez-Jaramillo, Patricio Cardona-Munoz, Ernesto G. Pirags, Valdis Pogosova, Nana Raubenheimer, Peter J. Shaw, Jonathan Sheu, Wayne H-H. Temelkova-Kurktschiev, Theodora The REWIND Trial Investigators |
| dc.contributor.researchgroup.spa.fl_str_mv |
Masira |
| description |
Digital |
| publishDate |
2018 |
| dc.date.issued.none.fl_str_mv |
2018-01-05 |
| dc.date.accessioned.none.fl_str_mv |
2022-02-22T14:04:44Z |
| dc.date.available.none.fl_str_mv |
2022-02-22T14:04:44Z |
| dc.type.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_6501 |
| status_str |
publishedVersion |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1111/dom.13028 |
| dc.identifier.uri.none.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/6095 |
| url |
https://doi.org/10.1111/dom.13028 https://repositorio.udes.edu.co/handle/001/6095 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.citationendpage.spa.fl_str_mv |
49 |
| dc.relation.citationissue.spa.fl_str_mv |
1 |
| dc.relation.citationstartpage.spa.fl_str_mv |
42 |
| dc.relation.citationvolume.spa.fl_str_mv |
20 |
| dc.relation.indexed.spa.fl_str_mv |
Scopus |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Diabetes, Obesity and Metabolism |
| dc.rights.spa.fl_str_mv |
© The Authors, John Wiley & Sons Ltd, 2018 |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_14cb |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/closedAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
| rights_invalid_str_mv |
© The Authors, John Wiley & Sons Ltd, 2018 Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_14cb |
| eu_rights_str_mv |
closedAccess |
| dc.format.extent.spa.fl_str_mv |
8 p |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Diabetes, Obesity and Metabolism |
| dc.publisher.place.spa.fl_str_mv |
Reino Unido |
| dc.source.spa.fl_str_mv |
https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13028 |
| institution |
Universidad de Santander |
| bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/fdfbbe4c-65d4-4425-af22-6cae38dcf4d9/download https://repositorio.udes.edu.co/bitstreams/35888ef7-6064-4bf6-a407-26229e373260/download https://repositorio.udes.edu.co/bitstreams/104e4e16-5ce7-4685-98ac-0a836524286f/download https://repositorio.udes.edu.co/bitstreams/928241cb-2b82-4238-8e59-b8b683503555/download |
| bitstream.checksum.fl_str_mv |
c07e8282a56b82ecbba53acb43a3cc41 38d94cf55aa1bf2dac1a736ac45c881c 5dbe86c1111d64f45ba435df98fdc825 d075c77ab6f78e747c9ed55cf9748aad |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Universidad de Santander |
| repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
| _version_ |
1808490845256548352 |
| spelling |
Gerstein, Hertzel C.8dbb4c88-f0dd-45f2-8bc4-590f0a1e3c3c-1Colhoun, Helen M.41617f18-e528-4e15-819a-0a30d7feb185-1Dagenais, Gilles R.649af40f-e7a9-4172-baac-8e6c95a8dc4e-1Diaz, Rafaelf2be4a74-501a-4e63-8bbd-965cbcf8c57b-1Lakshmanan, Marke4d26b36-1c41-49d9-9c19-d57fb2109f53-1Pais, Prem5abdbf77-3c3f-4396-8634-83723aa215b9-1Probstfield, Jeffreycce7af47-ba6b-4280-bbb5-4c0a46da5d7d-1Riddle, Matthew C.d5c956b6-8f40-43ca-83bc-4b130c672a99-1Ryden, Larse8666dad-aab3-446a-9e58-5e23a391873f-1Xavier, Denis88c9cf48-fa3b-45c6-be03-2cc79e59289d-1Atisso, Charles M.bf69a044-b8d3-45b0-9c70-531796526171-1Avezum, Alvaro8b920360-abb2-4ec8-b5ee-4e3f4e0b11eb-1Basile, Jan31df2eea-b661-4757-98a0-111336270810-1Chung, Namsik9a0d8ed9-0c50-442d-baa7-35828186bb71-1Conget, Ignacioc0327a53-3097-438b-9a40-d441f3c20758-1Cushman, William C.6e873915-69b2-4696-afa0-6d21bbeb3531-1Franek, Edwardc8fa48cd-c0c0-4e99-ad2b-29843fba16c4-1Hancu, Nicolae65f98f93-ff67-40b8-bfc7-c1fed7923dd1-1Hanefeld, Markolf411c9d9d-d3a2-4a87-b8e7-dbd8bc7c968e-1Holt, Shaun42264558-8dfa-4004-ad7d-065174c245a2-1Jansky, Petrbf8ec62a-6edc-439c-a698-2e4fa4172f04-1Keltai, Matyas65c5da4f-dca6-4e4f-aa9e-6c2ff81f2df9-1Lanas, Fernandod22b7fe4-9f1f-4028-a22b-be782ef03d3c-1Leiter, Lawrence A.bcdd3211-40b7-474d-9f6c-8a1051ceb9bf-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Cardona-Munoz, Ernesto G.26d6dda9-4aba-462c-a733-f6b1a1445854-1Pirags, Valdisc43a25fe-51ee-4b71-863e-54b03868e125-1Pogosova, Nana0f2fb5e5-6659-4562-96e6-74c03e0c46bf-1Raubenheimer, Peter J.260f749c-e594-4273-a34d-e926010f883c-1Shaw, Jonathan11b1203a-7603-4d75-9aa8-e42f1d87cbf5-1Sheu, Wayne H-H.d377b549-9728-486e-820f-f5e9d3ba834b-1Temelkova-Kurktschiev, Theodoraa08e998d-95f2-4139-ae16-bd8009965b60-1The REWIND Trial Investigators8699422c-f6af-4147-9a1f-d7bea5c2f580-1Masira2022-02-22T14:04:44Z2022-02-22T14:04:44Z2018-01-05DigitalThe aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged ≥50 years, with glycated haemoglobin (HbA1c) ≤9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or ≥2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5 mg) or placebo and followed within the ongoing Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial every 3 to 6 months. The primary cardiovascular outcome is the first occurrence of the composite of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke. Secondary outcomes include each component of the primary composite cardiovascular outcome, a composite clinical microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. Follow-up will continue until the accrual of 1200 confirmed primary outcomes. Recruitment of 9901 participants (mean age 66 years, 46% women) occurred in 370 sites located in 24 countries over a period of 2 years. The mean duration of diabetes was 10 years, mean baseline HbA1c was 7.3%, and 31% had prior cardiovascular disease. The REWIND trial's international scope, high proportion of women, high proportion of people without prior cardiovascular disease and inclusion of participants whose mean baseline HbA1c was 7.3% suggests that its cardiovascular and safety findings will be directly relevant to the typical middle-aged patient seen in general practice throughout the world.Ciencias Médicas y de la Salud8 papplication/pdfhttps://doi.org/10.1111/dom.13028https://repositorio.udes.edu.co/handle/001/6095engDiabetes, Obesity and MetabolismReino Unido4914220ScopusDiabetes, Obesity and Metabolism© The Authors, John Wiley & Sons Ltd, 2018info:eu-repo/semantics/closedAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_14cbhttps://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13028Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutideArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALDesign and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND).pdfDesign and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND).pdfapplication/pdf283529https://repositorio.udes.edu.co/bitstreams/fdfbbe4c-65d4-4425-af22-6cae38dcf4d9/downloadc07e8282a56b82ecbba53acb43a3cc41MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/35888ef7-6064-4bf6-a407-26229e373260/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTDesign and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND).pdf.txtDesign and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND).pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/104e4e16-5ce7-4685-98ac-0a836524286f/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILDesign and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND).pdf.jpgDesign and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND).pdf.jpgGenerated Thumbnailimage/jpeg6829https://repositorio.udes.edu.co/bitstreams/928241cb-2b82-4238-8e59-b8b683503555/downloadd075c77ab6f78e747c9ed55cf9748aadMD54001/6095oai:repositorio.udes.edu.co:001/60952023-10-09 18:06:42.873https://creativecommons.org/licenses/by-nc/4.0/© The Authors, John Wiley & Sons Ltd, 2018https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |